There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics Inc (VYGR), Synthetic Biologics Inc (SYN) and Alimera (ALIM) with bullish sentiments.
Voyager Therapeutics Inc (VYGR)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics Inc today and set a price target of $25. The company’s shares closed yesterday at $11.53, close to its 52-week low of $10.90.
Chattopadhyay observed:
“Our $25 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY-AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.38, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.1% and a 36.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Voyager Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $23.50.
See today’s analyst top recommended stocks >>
Synthetic Biologics Inc (SYN)
H.C. Wainwright analyst Edward White maintained a Buy rating on Synthetic Biologics Inc today and set a price target of $6. The company’s shares closed yesterday at $0.74, close to its 52-week low of $0.70.
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 43.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.
Currently, the analyst consensus on Synthetic Biologics Inc is a Moderate Buy with an average price target of $6.
Alimera (ALIM)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Alimera today and set a price target of $2.50. The company’s shares closed yesterday at $0.99.
Selvaraju wrote:
“We note that Mr. Eiswirth has served as President for three years and the company’s Chief Financial Officer (CFO) since 2005. Through our interactions, we feel that Mr. Eiswirth is well informed of the market dynamics in the ophthalmology sector and aptly experienced to execute new strategies to realize Iluvien’s full market potential. As part of the executive transition plan announced yesterday, Phil Jones, current Finance, will assume the role of CFO. Dave Holland, co-founder and currently U.S., will assume the titles of Managed Markets. Philip Ashman, currently Europe, will assume the titles of Operations Europe.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -12.6% and a 25.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alimera with a $2.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
